MAYO CLINIC LABORATORIES

NEW TEST

Notification Date: February 2, 2023
Effective Date: February 7, 2023

Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow

Test ID: MSMRD

Useful for:
Risk stratification of patients with treated multiple myeloma, which can assist in determining treatment and management decisions

Testing Algorithm:
Based on the flow cytometric analysis and the presence of greater than or equal to 0.1% monotypic plasma cells, pre-analysis cell sorting and fluorescence in situ hybridization for plasma cell proliferative disorders will be performed at an additional charge.
Based on the flow cytometric analysis and the absence of monotypic plasma cells, then minimal residual disease for multiple myeloma will be performed at an additional charge.

Ordering Guidance:
This test should be ordered on patients treated for multiple myeloma to confirm remission has been achieved, as an annual follow-up of those in remission or in uncertain remission, or when MPCDS / mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow is desired.

Reflex Tests:

Test ID	Reporting Name	Available Separately	Always Performed
CSMRT	MPCDS Pre-Analysis Cell Sorting, BM	No	No
MPCDS	mSMART Eval, PCPDs, FISH	Yes (Order PCPDS)	No
MRDMR	Multiple Myeloma MRD by Flow, BM	Yes (Order MRDMM)	No

Methods:
Flow Cytometry/DNA Content/Cell Cycle Analysis

Reference Values:
PLASMA CELL CLONALITY:
Normal bone marrow
No monotypic clonal plasma cells detected

DNA INDEX:
Normal polytypic plasma cells
DNA index (G0/G1 cells): Diploid 0.95-1.05

Specimen Requirements:

Specimen Type: Redirected bone marrow
Preferred: Yellow top (ACD)
Acceptable: Lavender top (EDTA)
Specimen Volume: 4 mL
Specimen Minimum Volume: 3 mL

Specimen Stability Information:

Specimen Type	Temperature	Time
Bone Marrow	Ambient (preferred)	72 hours
	Refrigerated	72 hours

Cautions:

This test report is best used for patients treated for multiple myeloma to confirm remission has been achieved or as an annual follow-up of those in remission or in uncertain remission. It is designed for patients with multiple myeloma and may not be applicable for monoclonal gammopathy of uncertain significance, smoldering myeloma, or amyloidosis.

This stratification system is not meant to replace existing prognostic systems such as the International Staging System.

CPT Code:

88182-Flow cytometry, cell cycle or DNA analysis

88184-Flow cytometry; first cell surface, cytoplasmic or nuclear marker

88185 x 5-Flow cytometry; additional cell surface, cytoplasmic or nuclear marker (each)

88187-Flow cytometry interpretation, 2 to 8 Markers

Day(s) Performed: Monday through Friday **Report Available:** 1 to 13 days

Questions

Contact Connie Penz, Laboratory Technologist Resource Coordinator at 800-533-1710.